Otezla Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber of Otezla (apremilast), you have likely encountered patients who cannot fill their prescription promptly — or at all. While Otezla is not on the FDA Drug Shortages Database in 2026 and Amgen's supply chain remains stable, patients face a complex web of access barriers that translate into real treatment delays. This guide summarizes the key access challenges you need to be aware of in 2026, along with practical strategies to help your patients start and maintain therapy.

The Current Access Landscape for Otezla in 2026

Otezla is not experiencing a supply shortage in 2026. However, several systemic access barriers make it one of the more challenging specialty medications to get into patients' hands:

Specialty pharmacy exclusivity: Otezla is dispensed only through specialty pharmacies. Patients who are unaware of this routing requirement may experience significant delays at the point of first fill.

Universal prior authorization requirements: Virtually all commercial payers, Medicare Part D plans, and Medicaid programs require PA for Otezla. Review turnaround times typically range from 1 to 4 weeks.

Widespread step therapy mandates: Most formularies require documented failure of one or more conventional systemic therapies (methotrexate, cyclosporine, acitretin) before approving Otezla. Some plans require biologic failure for PsA indications.

High list price, no US generic: Otezla carries a list price of approximately $5,000 to $6,800 per 30-day supply. No US generic is expected until approximately 2028-2029 following the April 2023 patent ruling.

Key Clinical Considerations: Who Benefits Most from Otezla?

Otezla has four FDA-approved indications: plaque psoriasis in adults (all severities) who are candidates for phototherapy or systemic therapy; moderate-to-severe plaque psoriasis in pediatric patients 6 years and older weighing at least 20 kg; active psoriatic arthritis in adults and qualifying pediatric patients; and oral ulcers associated with Behçet's disease in adults.

Otezla's most compelling clinical advantages for patient selection include its oral administration (no injections required), absence of routine laboratory monitoring requirements, and its mild-to-moderate immunosuppressive profile compared to biologics. It is particularly well-suited for patients who have relative contraindications to biologics (active or recurrent infections, demyelinating disorders, or concerns about immunosuppression), patients who strongly prefer an oral option, and patients with mild-to-moderate disease burden who may not meet biologic criteria.

However, be aware that Otezla is generally less effective than biologics for skin clearance. Clinical evidence from the LIBERATE trial and network meta-analyses consistently demonstrates biologics achieve higher PASI response rates than apremilast. For patients with severe disease or those requiring rapid clearance, biologics should be considered as primary options.

Optimizing the Prior Authorization Process

The quality of your PA submission is the single most important factor in how quickly your patients access Otezla. Incomplete PA requests are a leading cause of delays and initial denials. To maximize approval rates and speed, PA documentation for Otezla should include:

Specific diagnosis with ICD-10 code and severity documentation (BSA involvement, PASI score where applicable)

Documentation of all prior systemic therapies tried, including dates, duration, doses, and specific reasons for discontinuation (failure, intolerance, or contraindication)

Clinical rationale for why Otezla is preferred over continued step therapy alternatives

Any relevant comorbidities or contraindications to required step therapy drugs (e.g., hepatic disease contraindicating methotrexate, renal disease affecting cyclosporine)

Recent lab results, photographs of skin involvement, or functional impairment documentation as supporting evidence

The Bridge Program: Getting Patients on Therapy While Waiting for Approval

Amgen's Bridge to Commercial Coverage program is one of the most clinically valuable tools available for managing Otezla access. For commercially insured patients who face a PA delay or denial, this program provides free Otezla for up to 12 prescription fills within 12 months. Enrollment is managed through Amgen SupportPlus and is triggered automatically when a PA delay is identified.

Practically, this means your patients can start the Otezla titration schedule immediately — beginning the clinical benefit window — rather than waiting weeks for insurance resolution. Early initiation also allows you to assess tolerability and efficacy before the insurance determination, providing valuable clinical data to support an appeal if needed.

When to Consider Alternatives to Otezla

When access barriers to Otezla are insurmountable or the patient's disease is severe enough to warrant more aggressive therapy, consider the following alternatives: methotrexate for cost-sensitive patients who can tolerate lab monitoring; deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis patients who want a potentially more effective oral option; TNF inhibitors (adalimumab and biosimilars) or IL-17 inhibitors (secukinumab/Cosentyx) for patients requiring stronger efficacy, especially those with active joint disease.

medfinder for Providers: Helping Your Patients Find Their Medication

When patients leave your office with an Otezla prescription and encounter access barriers, the resulting treatment gaps can frustrate both parties and lead to disease worsening. medfinder is a service that helps patients locate pharmacies that can fill their specific prescription. Recommending medfinder to your patients as a resource can reduce the administrative burden on your office while helping patients navigate the specialty pharmacy landscape more effectively. For a complete workflow guide, see How to Help Your Patients Find Otezla in Stock: A Provider's Guide.